Teladoc Health (NYSE:TDOC) Updates FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of -1.000–0.750 for the period, compared to the consensus earnings per share estimate of -0.810. The company issued revenue guidance of $2.4 billion-$2.4 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q3 2026 guidance to -0.300–0.200 EPS.

Teladoc Health Price Performance

Shares of Teladoc Health stock traded down $0.15 during trading on Wednesday, hitting $9.21. 7,802,316 shares of the stock traded hands, compared to its average volume of 5,394,875. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -9.50 and a beta of 2.10. The firm’s fifty day moving average is $8.16 and its 200-day moving average is $6.54. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Research analysts expect that Teladoc Health will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on TDOC. Canaccord Genuity Group lifted their price target on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Citigroup upped their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Bank of America lifted their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.57.

Insider Activity

In other Teladoc Health news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $43,315.51. Following the completion of the sale, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. This represents a 37.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the completion of the sale, the insider directly owned 57,671 shares in the company, valued at approximately $440,029.73. This trade represents a 9.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 39,195 shares of company stock worth $299,058. 0.70% of the stock is currently owned by corporate insiders.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported second-quarter adjusted EPS of $(0.21), better than the consensus estimate of $(0.24). Operating cash flow was $64.7 million, and the company ended the quarter with $774.3 million in cash and equivalents, supporting its liquidity position. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: Some valuation analysis continues to view TDOC as potentially undervalued after its substantial long-term decline, suggesting upside if the company can stabilize revenue and improve profitability. Teladoc Health Stock Still Looks Undervalued
• Neutral Sentiment: Institutional positioning was mixed: 151 investors increased their holdings in the latest quarter, while 126 reduced positions. This indicates continued interest but no clear consensus among large investors.
• Negative Sentiment: Second-quarter revenue fell 3.95% year over year to $606.9 million, missing the $627.7 million consensus estimate. Gross profit was $416.1 million, while the operating loss widened to $37.1 million, underscoring ongoing profitability challenges. Teladoc Health Q2 2026 Earnings
• Negative Sentiment: Management’s outlook was below Wall Street expectations. Third-quarter revenue guidance of $569 million to $609 million trails the $629.1 million estimate, while projected EPS of $(0.30) to $(0.20) is worse than the $(0.17) consensus. Full-year revenue guidance of approximately $2.4 billion also falls short of the $2.5 billion forecast.
• Negative Sentiment: Insiders reported 18 open-market sales and no purchases over the past six months. In addition, the median analyst price target of $7 is below recent trading levels, potentially limiting near-term upside.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC raised its position in Teladoc Health by 236.6% during the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after purchasing an additional 26,494 shares during the last quarter. Mackenzie Financial Corp grew its position in shares of Teladoc Health by 38.6% in the 4th quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock worth $1,157,000 after buying an additional 46,090 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Teladoc Health by 1.9% during the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after buying an additional 14,029 shares during the period. Voloridge Investment Management LLC increased its stake in shares of Teladoc Health by 42.8% during the fourth quarter. Voloridge Investment Management LLC now owns 997,427 shares of the health services provider’s stock valued at $6,982,000 after buying an additional 299,086 shares during the period. Finally, Polymer Capital Management US LLC increased its stake in shares of Teladoc Health by 32.0% during the fourth quarter. Polymer Capital Management US LLC now owns 22,443 shares of the health services provider’s stock valued at $157,000 after buying an additional 5,443 shares during the period. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.